Compounded tirzepatide
Sold by OrderlyMeds · Injection, vial · every compounded tirzepatide record
What you actually pay
Per month
$299
| Medication · Monthly plan | $299 |
|---|
Added from the figures recorded below.
Price
| Term | Per month | Charged today |
|---|---|---|
| Monthly plan “Compounded Tirzepatide GLP-1 injections $299” source, read September 2, 2026 | Per month$299 | Charged today$299 |
| 2 month starter program “Compounded Tirzepatide GLP-1/GIP injections $149/mo $299 for 2 months” source, read September 2, 2026 | Per month$149 | Charged today$299 |
| 2 month special offer “Compounded Tirzepatide GLP-1/GIP injections $224/mo $449 for 2 months” source, read September 2, 2026 | Per month$224 | Charged today$449 |
We earn nothing from this link. OrderlyMeds has no commercial arrangement with Treatment Registry, and its record here is kept to the same standard as every other.
History
- September 2, 2026 — $299
- September 3, 2026 — $299
- September 2, 2026 — Entry added to the register
Sourcing and terms
| States | All 50 states |
|---|---|
| Prescriber | Asynchronous review |
| Cancellation | “When you sign up, you can cancel any time before the doctor finalizes your prescription, unless you've selected a multi-month plan. Our standard sign-up process includes month-to-month plans as well as multi-month options.” |
| Membership | None. “We have no membership fees or hidden costs-what you see is what you pay!” |
Not yet checked: pharmacy and consult fee.
Recorded from orderlymeds.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.
Notes
- 1. September 2, 2026 — Compounded product pages confirm shipments include 'your medication vial,' so compounded entries are recorded as injection-vial; brand pages explicitly say '(GLP-1 pen)' / '(GLP-1/GIP pen)' for Wegovy/Zepbound.
Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.